Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapy for patients with advanced hematologic malignancy, including those with AML.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapy for patients with advanced hematologic malignancy, including those with AML. 1 However, allo-HSCT after conventional myeloablative conditioning (MAC) may be associated with a high rate of transplant-related complications. Reduced intensity conditioning (RIC) was developed with the purpose of reducing regimen-related toxicity. 2, 3 RIC is increasingly used for allo-HSCT for AML patients who are otherwise considered unfit for MAC.
The primary objective of low-dose TBI in RIC is inhibition of the host immune response to facilitate engraftment. 4, 5 Several studies have suggested that the addition of low-dose TBI to the conditioning regimen improved outcomes of transplantation. 6, 7 However, favorable outcomes of non-TBI-based RIC transplantation were also reported. 8 Thus, the impact of low-dose TBI on outcomes after allo-HSCT remains controversial, and it is unknown whether the addition of low-dose TBI to RIC is beneficial for AML patients. Therefore, we conducted a retrospective analysis to elucidate the clinical impact of low-dose TBI on outcomes after allo-HSCT from a HLA-matched-related donor in the setting of fludarabine-based RIC.
Clinical data were collected from the registry database of the Japan Society for Hematopoietic Cell Transplantation. Patients with AML (excluding acute promyelocytic leukemia) aged 16 years or older who underwent fludarabine-based RIC allo-HSCT from an HLA-matched-related donor between January 2000 and December 2012 were extracted from the database. Patients who underwent two or more HSCT were excluded. We retrospectively analyzed the clinical impact of low-dose TBI on outcomes after RIC allo-HSCT. Overall survival (OS), relapse, nonrelapse mortality (NRM) and hematological recovery of patients who received low-dose TBI as a part of fludarabine-based RIC (TBI group) were compared with those of patients who did not receive TBI (non-TBI group). Low-dose TBI was defined as ⩽ 4 Gy, as previously reported. 9 Fludarabine-based RIC was defined as RIC containing fludarabine 120-180 mg/m 2 . Definitions of RIC other than TBI were as follows: oral busulfan o9 mg/kg (or IV injection in equivalent doses) or melphalan ⩽ 140 mg/m 2 . 10 Cytogenetic subgroups were classified according to the Southwest Oncology Group (SWOG) definition. 11 Neutrophil engraftment was defined as the continuous achievement of neutrophil counts 500 × 10 6 /l or higher. Platelet recovery was also defined as continuous achievement of neutrophil counts 50 × 10 9 /l or higher without transfusion. This study was approved by the Institutional Review Board of the Kanagawa Cancer Center. Table 1 shows patients characteristics. Of the 409 patients, 108 patients were in the TBI group and 301 patients were in the non-TBI group. A higher proportion of patients underwent bone marrow transplantation (BMT) (P o 0.001) and received cyclosporine for GvHD prophylaxis (P = 0.006) in the TBI group. The proportion of male patients (P = 0.07) and patients who underwent allo-HSCT between 2000 and 2007 (P = 0.09) tended to be lower in the TBI group. There was no difference in other factors, including age at allo-HSCT, disease status, performance status, cytogenetic risk category and conditioning regimen other than TBI when comparing the TBI group and the non-TBI group.
Five-year OS was not significantly different when comparing the two groups (36.0% for the TBI group vs 32.8% for the non-TBI group, P = 0.66). In multivariate analysis of the entire cohort and of subgroups stratified by stem cell source (peripheral blood stem cell transplantation (PBSCT) and BMT), low-dose TBI had no significant effect on OS after adjusting for covariates (hazard ratio (HR) 1.06; 95% confidence interval (CI) 0.79-1.42; P = 0.70 in the entire cohort, HR 1.01; 95% CI 0.67-1.53; P = 0.96 in PBSCT and HR Table 2 ). The cumulative neutrophil recovery at 30 days after transplantation was lower in the TBI group than in the non-TBI group (90.7% for the TBI group vs 93.0% for the non-TBI group, P = 0.03). However, subgroup analysis stratified by stem cell source showed no significant difference in neutrophil engraftment (89.6% for the TBI group vs 93.2% for the non-TBI group, P = 0.21 in PBSCT and 91.5% for the TBI group vs 92.6% for the non-TBI group, P = 0.39 in BMT). Similarly, although the cumulative platelet recovery at 60 days after transplantation was lower in the TBI group than in the non-TBI group (74.5% for the TBI group vs 79.3% for the non-TBI group, P = 0.04), there was no significant difference in platelet recovery in subgroup analysis stratified by the stem cell source (83.0% for the TBI group vs 82.0% for the non-TBI group, P = 0.52 in PBSCT and 67.8% for the TBI group vs 73.4% for the non-TBI group, P = 0.29 in BMT). In multivariate analysis of entire cohort, the probability of neutrophil recovery in the TBI group tended to be lower (HR 0.81; 95% CI 0.65-1.01; P = 0.06). However, multivariate analysis of subgroups stratified by stem cell source showed low-dose TBI was not significantly associated with neutrophil recovery (HR 0.79; 95% CI 0.58-1.07; P = 0.12 in PBSCT and HR 0.85; 95% CI 0.62-1.17; P = 0.33 in BMT). Multivariate analysis of the entire cohort and of subgroups stratified by stem cell source showed low-dose TBI did not affect platelet recovery (HR 0.88; 95% CI 0.69-1.14; P = 0.34 in the entire cohort, HR 0.99; 95% CI 0.71-1.40; P = 0.98 in PBSCT and HR 0.84; 95% CI 0.58-1.21; P = 0.35 in BMT; Table 2 ). The current analysis showed that OS, relapse and NRM were comparable between the TBI group and the non-TBI group. The cumulative probability of neutrophil and platelet recovery was lower in the TBI group than in the non-TBI group, mainly because the proportion of patients receiving BMT was higher in the TBI group. However, subgroup analysis stratified by stem cell source revealed that hematopoietic recoveries were similar when comparing the two groups. Furthermore, multivariate analyses of the entire cohort and subgroups stratified by stem cell source showed that low-dose TBI had no significant impact on neutrophil and platelet engraftments. These findings suggested that sufficient hematopoietic recovery could be achieved without TBI in RIC allo-HSCT from an HLA-matched-related donor, as previously reported. 12, 13 In contrast, Rodrigues et al. reported that the addition of low-dose TBI to a RIC regimen improved neutrophil recovery and survival after cord blood transplantation. 7 Low-dose TBI may be important in the setting of unrelated donor transplantation. 4 Russell et al. described the effect of the addition of low-dose TBI to a MAC regimen in AML patients. 6 They added 4 Gy of TBI to a regimen incorporating busulfan, fludarabine and antithymocyte globulin. Additional TBI reduced the relapse rate without affecting the NRM. However, the current study indicated that the addition of low-dose TBI to fludarabine-based RIC did not affect the relapse rate. Differences in the intensity of regimens appear to be the cause of this discrepancy.
This analysis had several limitations. First, data regarding long-term complications were not available. Several studies have described the late complications of TBI, such as cataract, pulmonary injury, kidney dysfunction and secondary malignancies. 4 Although the current study showed a similar NRM rate between the TBI group and the non-TBI group, the addition of low-dose TBI may negatively affect long-term survivors after RIC allo-HSCT. Second, we did not examine the impact of other factors, such as minimal residual disease and molecular markers. Physicians might make a decision for low-dose TBI according to those factors, for example, FLT3-ITD mutation. There is a possibility that low-dose TBI was favored for patients with unexamined high-risk status for graft failure, leading to the artificial appearance of an inferior hematopoietic recovery in the TBI group. Third, the number of patients in this study may have been too small to accurately detect the effect of low-dose TBI.
In conclusion, our study revealed that the addition of low-dose TBI to RIC do not improve outcomes, including donor cell engraftment, of RIC allo-HSCT from an HLA-matched-related donor. Abbreviations: BMT = bone marrow translantation; CI = confidence interval; HR = hazard ratio; NRM = non-relapse mortality; OS = overall survival; PBSCT = peripheral blood stem cell transplantation. HR of the TBI group was shown after adjusting for the factors of Po0.1 in univariate analysis with stepwise deletions among age, gender, disease status, performance status, GvHD prophylaxis, cytogenetic risk category, donor sources and conditioning regimen other than TBI.
Letter to the Editor
